GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxcyte Inc (NAS:PCVX) » Definitions » Capex-to-Operating-Income

Vaxcyte (Vaxcyte) Capex-to-Operating-Income : 0.00 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Vaxcyte Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Vaxcyte's Capital Expenditure for the three months ended in Mar. 2024 was $-12.07 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-114.35 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Vaxcyte Capex-to-Operating-Income Historical Data

The historical data trend for Vaxcyte's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxcyte Capex-to-Operating-Income Chart

Vaxcyte Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial - - - - -

Vaxcyte Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vaxcyte's Capex-to-Operating-Income

For the Biotechnology subindustry, Vaxcyte's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaxcyte's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxcyte's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Vaxcyte's Capex-to-Operating-Income falls into.



Vaxcyte Capex-to-Operating-Income Calculation

Vaxcyte's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-67.877) / -388.276
=N/A

Vaxcyte's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-12.072) / -114.346
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vaxcyte  (NAS:PCVX) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Vaxcyte Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Vaxcyte's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaxcyte (Vaxcyte) Business Description

Industry
Traded in Other Exchanges
Address
825 Industrial Road, Suite 300, San Carlos, CA, USA, 94070
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-XP, VAX-A1, and VAX-PG.
Executives
Andrew Guggenhime officer: CFO, CBO C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Grant Pickering director, officer: President & CEO C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Mikhail Eydelman officer: SVP, Gen Counsel & Corp Sec C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS CA 94070
Jim Wassil officer: Chief Operating Officer C/O VAXCYTE, INC., 353 HATCH DRIVE, FOSTER CITY CA 94404
Heath Lukatch director 326 BOLLAY DRIVE, GOLETA CA 93117
Elvia Cowan officer: See Remarks Section C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS CA 94070
Jeff Fairman officer: VP, Research C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Paul Sauer officer: SVP Process Dev, Manufacturing C/O VAXCYTE, INC., 825 INDUSTRIAL DRIVE, STE. 300, SAN CARLOS CA 94404
Michael E. Kamarck director C/O UNILIFE CORPORATION, 250 CROSS FARM LANE, YORK PA 17406
Carlos V Paya director C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Harpreet S. Dhaliwal officer: SVP Cml Mfg & Supply Chain C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Anne S Drapeau director C/O IRON MOUNTAIN INCORPORATED, ONE FEDERAL STREET, BOSTON MA 02110
Teri Loxam director C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Jane Wright Mitchell officer: General Counsel C/0 ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Robert Lorne Hopfner director C/O BAY CITY CAPITAL, LLC, 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111